Prevalence and Risk Factor Determining Autoimmune Rheumatic Disease and Malignancy
Asian Journal of Immunology,
Page 15-24
Abstract
Background: A determine prevalence and identify risk factors of malignancy in autoimmune rheumatic diseases were important for raising awareness of the association between autoimmune rheumatic diseases and malignancy leading to more effective treatments.
Objective: To determine prevalence and risk factors of malignancy in autoimmune rheumatic diseases patients.
Methods: A cross-sectional study was conducted on medical records of patients diagnosed with autoimmune rheumatic diseases and malignancy based on the ICD-10 coding system from January 1, 2013-May 31 2020, at a tertiary referral hospital in Bangkok.
Results: From records of patients diagnosed with autoimmune rheumatic diseases, most were patients with systemic lupus erythematosus (n=2,277), rheumatoid arthritis (n=530), spondyloarthritis (n=379), systemic sclerosis (n=290), dermato/ polymyositis (n = 108), Sjögren syndrome (n=95), and overlap syndrome (n=54). The overall prevalence rate of malignancy in autoimmune rheumatic diseases was 4.2%. Lung and breast were the most common sites. Types of autoimmune rheumatic diseases, age groups, comorbid, and medications were risk factors that could heighten malignancy risk in autoimmune rheumatic diseases. Amongst types of autoimmune rheumatic diseases, demato/ polymyositis and rheumatoid arthritis were heighten risk of malignancy up to 3.88 and 2.60 times over systemic lupus erythematosus. Patients with over 60 years had the higher risk at 3.21 times over those age between 15-25 years. Comorbid disease brought 1.50 times higher risk. As cyclophosphamide, corticosteroids and methrotrexate, some medications increased the risk ranged between 2.79, 1.93 and 0.56 times, respectively.
Conclusions: Evidence confirmed the association of malignancy with all kinds of autoimmune rheumatic diseases, especially rheumatoid arthritis and dermato/ polymyositis, at the highest risk. The study indicated an increased risk of malignancy among elders, patients with comorbid, and corticosteroids, cyclophosphamide, and methrotrexate users.
Keywords:
- Autoimmune rheumatic disease
- cancer
- malignancy
- prevalence
- risk factor.
How to Cite
References
Turesson C, Matteson EL. Malignancy as a comorbidity in rheumatic diseases. Rheumatology (Oxford). 2013;52(1):5-14.
Van der Heijde D, Daikh DI, Betteridge N, Burmester GR, Hassett AL, Matteson EL, et al. Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Ann Rheum Dis. 2018;77(6):829-32.
Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45.
Ni J, Qiu LJ, Hu LF, Cen H, Zhang M, Wen PF, et al. Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis. Lupus. 2014;23(3):284-92.
Wilton KM, Matteson EL. Malignancy incidence, management, and prevention in patients with rheumatoid arthritis. Rheumatol Ther. 2017;4(2):333-47.
Shah AA, Casciola-Rosen L. Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening. Curr Opin Rheumatol. 2015;27(6):563-70.
Machado RI, Braz Ade S, Freire EA. Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review. Rev Bras Reumatol. 2014;54(2):131-9.
Shiff NJ, Lix LM, Joseph L, Duffy C, Tucker LB, Svenson LW, et al. The prevalence of systemic autoimmune rheumatic diseases in Canadian pediatric populations: administrative database estimates. Rheumatol Int. 2015;35(3):569-73.
Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223-43.
Gleicher N, Barad DH. Gender as risk factor for autoimmune diseases. J Autoimmun. 2007;28(1):1-6.
Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173(3):600-9.
Jakubaszek M, Kwiatkowska B, Maślińska M. Polymyositis and dermatomyositis as a risk of developing cancer. Reumatologia. 2015;53(2):101-5.
Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326(6):363-7.
Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population- based study. Lancet. 2001;357(9250):96-100.
Chen YJ, Chang YT, Wang CB, Wu CY. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum. 2011;63(2):352-8.
Fact sheet: Thailand - Global Cancer Observatory Globocan 2020: International agency for Research in Cancer. WHO; December 2020. [updated December, 2020].
Available:https://gco.iarc.fr/today/data/factsheets/populations/764-thailand-fact-sheets.pdf
Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119-25.
Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, et al. Breast cancer in systemic lupus. Lupus. 2017;26(3):311-5.
Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, Rojas-Villarraga A, Anaya JM. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun. 2012;38(2-3):J109-19.
Egiziano G, Bernatsky S, Shah AA. Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link. Best Pract Res Clin Rheumatol. 2016;30(1):53-62.
Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol. 2008;8(12):970-6.
Salazar-Onfray F, López MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev. 2007;18(1-2):171-82.
Ortiz A, Gonzalez-Parra E, Alvarez-Costa G, Egido J. Bladder cancer after cyclophosphamide therapy for lupus nephritis. Nephron. 1992;60(3):378-9.
Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Annals of the Rheumatic Diseases. 2006;65(5):617-22.
Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50(6):1740-51.
Shah AA, Casciola-Rosen L. Mechanistic and clinical insights at the scleroderma- cancer interface. J Scleroderma Relat Disord. 2017;2(3):153-9.
Tessier-Cloutier B, Clarke AE, Pineau CA, Keeling S, Bissonauth A, Ramsey-Goldman R, et al. What investigations are needed to optimally monitor for malignancies in SLE? Lupus. 2015; 24(8):781-7.
-
Abstract View: 113 times
PDF Download: 76 times
